Enovis Corporation (NYSE:ENOV) Receives Average Recommendation of “Buy” from Analysts

Enovis Corporation (NYSE:ENOV) has been given an average recommendation of “Buy” by the nine analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $47.4286.

Several equities research analysts recently commented on ENOV shares. Canaccord Genuity Group decreased their target price on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. UBS Group restated a “buy” rating and set a $50.00 price target on shares of Enovis in a report on Monday, January 5th. BTIG Research raised their price objective on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Evercore reiterated an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Finally, Wells Fargo & Company raised shares of Enovis to a “strong-buy” rating in a research note on Wednesday.

Insider Activity

In other news, insider Oliver Engert bought 1,000 shares of Enovis stock in a transaction dated Friday, February 27th. The stock was bought at an average cost of $25.50 per share, for a total transaction of $25,500.00. Following the purchase, the insider directly owned 43,640 shares in the company, valued at approximately $1,112,820. This represents a 2.35% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have bought 5,000 shares of company stock worth $121,983. 2.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enovis

Hedge funds have recently added to or reduced their stakes in the company. Arax Advisory Partners bought a new stake in shares of Enovis during the fourth quarter valued at approximately $29,000. Farther Finance Advisors LLC lifted its holdings in shares of Enovis by 42.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after purchasing an additional 367 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the period. Elevation Point Wealth Partners LLC acquired a new stake in Enovis in the 2nd quarter valued at $46,000. Finally, SJS Investment Consulting Inc. increased its stake in Enovis by 30,340.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock valued at $46,000 after purchasing an additional 1,517 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Price Performance

ENOV stock opened at $21.74 on Friday. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -1.05 and a beta of 1.46. The company’s fifty day simple moving average is $23.26 and its 200 day simple moving average is $27.54. Enovis has a 12-month low of $21.00 and a 12-month high of $40.69.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. The firm had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The business’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the business posted $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts expect that Enovis will post 2.79 earnings per share for the current year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.